Translate Bio Appoints Pasquale (Pat) Sacco as Senior Vice President of Technical Operations
April 01, 2019 07:30 ET
|
Translate Bio, Inc.
-- New role expands Company’s manufacturing expertise to support pipeline of mRNA therapeutics in development for rare, genetic diseases -- LEXINGTON, Mass., April 01, 2019 (GLOBE NEWSWIRE) --...
Translate Bio Granted U.S. Patent Relating to Messenger RNA (mRNA) Delivery
March 26, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Participate in Upcoming Investor Conferences
March 25, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights
March 21, 2019 16:29 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy
March 18, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
February 14, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT™)
December 04, 2018 09:15 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights
November 08, 2018 16:21 ET
|
Translate Bio, Inc.
Continued progress with ongoing Phase 1/2 clinical trial in CF and towards IND submission for OTC Deficiency LEXINGTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a...
Translate Bio to Participate in Upcoming Investor Conferences
November 01, 2018 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference
October 18, 2018 07:30 ET
|
Translate Bio, Inc.
-- Findings support ongoing Phase 1/2 study of once-weekly nebulized MRT5005 in adults with cystic fibrosis -- LEXINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq:...